Nadolol and Bendroflumethiazide Tablets

This is a preview of
USP-NF/PF content.

Subscriber?
Access here!Not a subscriber?
Learn more!

BRIEFING

Nadolol and Bendroflumethiazide Tablets. This proposal is based on the version of the monograph official May 1, 2021. It is proposed to omit this monograph for the following reasons:

No drug products formulated as defined under Nadolol and Bendroflumethiazide Tablets are currently marketed in the United States.
The drug product is currently not on the list for approved veterinary medicine in the United States.

(SM6: L. Ahmad)

Case ID—SUB-1870

USP REFERENCE STANDARDS FOR PURCHASE

USP 2,4-Disulfamyl-5-trifluoromethylaniline RS
USP Bendroflumethiazide RS
USP Nadolol RS

This is a preview of
USP-NF/PF content.

Subscriber?
Access here!Not a subscriber?
Learn more!